Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC

Share :
Published: 27 Oct 2023
Views: 32
Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Dr Neil Gross speaks to ecancer about the study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma. 

In part one of the study, patients with resectable stage II-IV CSCC were given neoadjuvant cemiplimab 350 mg every 3 weeks for up to 4 doses, followed by curative-intent surgery.

In the second part of the study, patients were given adjuvant cemiplimab for up to 48 weeks, or radiotherapy, or observation only, as per the investigator's discretion. 

The study concluded that neoadjuvant cemiplimab showed favourable EFS, DFS, and OS rates in patients with resectable stage II-IV CSCC. Those who achieved pCR had no recurrences after a median follow-up of 18.7 months. 

Furthermore, there were no new safety signals with cemiplimab.